Portal de Periódicos da CAPES

An Open-Label Pilot Study of Methylphenidate in the Treatment of Cocaine Dependent Patients with Adult Attention Deficit/ Hyperactivity Disorder

2004; Taylor & Francis; Volume: 23; Issue: 1 Linguagem: Inglês

10.1300/j069v23n01_07

1545-0848

Eugene Somoza, Theresa Winhusen, T. Peter Bridge, John Rotrosen, Douglas Vanderburg, Judy M. Harrer, Juris P. Mezinskis, Margaret A. Montgomery, Domenic A. Ciraulo, Lawson R. Wulsin, Jera A. Barrett,

Substance Abuse Treatment and Outcomes

A multi-site, open-label study of methylphenidate for treating patients with comorbid diagnoses of attention deficit/hyperactivity disorder and cocaine dependence was performed. Forty-one participants, who met DSM-IV criteria for adult attention deficit/hyperactivity disorder and cocaine dependence, were enrolled into this ten week outpatient study. The targeted total daily dose of methylphenidate was 60 mg (20 mg TID). Participants received individual substance abuse therapy throughout the trial. Safety measures included adverse events, vital signs, and electrocardiograms. Methylphenidate's efficacy was assessed by both objective and subjective measures. Seventy percent of the participants completed final study measures. Safety measures indicated that methylphenidate was well tolerated by the participants. Subjective efficacy measures suggested that participants evidenced improvement in both cocaine dependence and adult attention deficit/hyperactivity disorder symptoms. Quantitative benzoylecgonine indicated that only those participants categorized as being compliant showed improvement. A double-blind, placebo-controlled study of methylphenidate for this population may be warranted.